A new method for monitoring melanoma patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates a novel follow-up approach for patients with low and intermediate risk melanoma (stages IA-IIA). It compares various patient support and education tools, along with clinician-supported skin self-examination (SSE), against the current standard care. The goal is to reduce fear of cancer recurrence and encourage regular SSE without compromising the detection of new melanomas or metastases.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Ability to read and understand Danish language
* Willing and able to give written informed consent
* Surgical treatment of a clinical stage IA-IIA melanoma within 3 months of inclusion

Exclusion Criteria:

* Advanced melanoma, clinical stages IIB, IIC, III, or IV
* Patients with high risk of a new primary melanoma (dysplastic nevus syndrome, or family history of melanoma)
* History of melanoma skin cancer prior to the index diagnosis
* Previous cancer, excluding non-melanoma skin cancer
* Comorbidity that makes skin self-examination impossible (e.g. physical or mental disabilities, dementia or decreased cognitive function)
* non-detection of sentinel node in IB and IIA patients

Where it's running

• Herlev and Gentofte Hospital
  Copenhagen, Denmark Recruiting

Study contacts

• Study coordinator: Sara M Hansen, MD
• Email: sara.moelgaard.hansen@regionh.dk
• Phone: +4538681296

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Early anti-PD1 therapy before surgery in high-risk stage II melanoma

  This study looks at real-world patients with high-risk stage II melanoma to see if starting anti-PD1 therapy before surgery changes outcomes compared with the usual timing.

  Recruiting AC Camargo Cancer Center · São Paulo, São Paulo · NCT07680699

• Guiding melanoma surgery in children using pathology and genetics

  This pediatric phase 2 trial tests whether using tumor pathology and genetic information to classify risk can guide safer, more appropriate surgery for localized skin melanocytic tumors.

  Recruiting at 13 sites Phase 2 Children's Oncology Group · Oakland, California and 12 other locations · NCT07621614

• First-in-human test of KUP-101A in selected advanced skin cancers

  This early study tests KUP-101A to see if it's safe and tolerable and to gather initial clues about its activity in patients with advanced skin cancers.

  Recruiting at 3 sites Phase 1 Kupando GmbH · Munich, Bavaria and 2 other locations · NCT07600476

• Phase 1 of PF-08046033 for advanced non-small-cell lung cancer, esophageal squamous cell cancer, and cutaneous melanoma

  This Phase 1 study will try the experimental antibody-drug conjugate PF-08046033 in adults whose non-small-cell lung cancer, esophageal squamous cell cancer, or cutaneous melanoma has progressed after standard treatments.

  Recruiting at 20 sites Phase 1 Pfizer · Denver, Colorado and 20 other locations · NCT07519655

• Work-related sun exposure and skin melanoma in the Modena area

  This project will see if people who work outdoors in the Modena area are more likely to develop types of melanoma linked to long-term sun exposure.

  Recruiting University of Modena and Reggio Emilia · Modena, Mo · NCT07251335

• Symptoms from immune checkpoint inhibitor therapy for cutaneous melanoma

  We will follow adults with stage IIB–IV cutaneous melanoma who are receiving immune checkpoint inhibitors to see how their symptoms change over time and which factors are linked to worse symptom patterns.

  Recruiting University of California, San Francisco · San Francisco, California · NCT07148245

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.